Loading
Before any academic compound gets money for pre-trial studies, it would have to show activity in a standard panel of patient-derived tumour models run by an independent centre, so weak candidates are stopped early.
A central facility maintains a standardised, molecularly characterised panel of patient-derived organoids and xenografts across cancer types (drawing on EurOPDX, the NCI Patient-Derived Models Repository and Human Cancer Models Initiative collections) and tests every candidate nominated for IND-enabling funding in a blinded, pre-registered protocol with clinically relevant exposure. Results are published regardless of outcome. Funding for toxicology and CMC is contingent on passing pre-agreed activity criteria. This replaces the variable, investigator-run efficacy evidence that currently supports translational decisions.
Shares Cancer Models (PDCM Finder) & HCMI, Patient-derived xenografts, Functional (ex vivo) drug testing, Patient-derived organoids.
Shares Patient-derived organoids to pick ADC payloads, Patient-derived xenografts, Functional (ex vivo) drug testing, Patient-derived organoids.
Shares Cancer Models (PDCM Finder) & HCMI, Patient-derived xenografts, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Cancer Models (PDCM Finder) & HCMI, Patient-derived xenografts, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Patient-derived organoids to pick ADC payloads, Functional (ex vivo) drug testing, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Cancer Models (PDCM Finder) & HCMI, Patient-derived xenografts, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Patient-derived xenografts, Patient-derived organoids, The valley of death between lab and product.
Shares Cancer Models (PDCM Finder) & HCMI, Functional (ex vivo) drug testing, Patient-derived organoids, Lab models that fail to predict what happens in patients.